Free Trial
NASDAQ:UBX

UNITY Biotechnology (UBX) Stock Price, News & Analysis

UNITY Biotechnology logo
$0.18 -0.12 (-40.43%)
Closing price 07/8/2025 07:59 PM Eastern
Extended Trading
$0.18 0.00 (0.00%)
As of 07/8/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About UNITY Biotechnology Stock (NASDAQ:UBX)

Key Stats

Today's Range
$0.20
$0.32
50-Day Range
$0.18
$1.12
52-Week Range
$0.20
$3.10
Volume
3.73 million shs
Average Volume
275,416 shs
Market Capitalization
$3.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.75
Consensus Rating
Moderate Buy

Company Overview

UNITY Biotechnology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
84th Percentile Overall Score

UBX MarketRank™: 

UNITY Biotechnology scored higher than 84% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    UNITY Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    UNITY Biotechnology has only been the subject of 3 research reports in the past 90 days.

  • Read more about UNITY Biotechnology's stock forecast and price target.
  • Earnings Growth

    Earnings for UNITY Biotechnology are expected to grow in the coming year, from ($1.45) to ($1.23) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of UNITY Biotechnology is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of UNITY Biotechnology is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    UNITY Biotechnology has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about UNITY Biotechnology's valuation and earnings.
  • Percentage of Shares Shorted

    3.65% of the float of UNITY Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    UNITY Biotechnology has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in UNITY Biotechnology has recently decreased by 34.44%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    UNITY Biotechnology does not currently pay a dividend.

  • Dividend Growth

    UNITY Biotechnology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.65% of the float of UNITY Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    UNITY Biotechnology has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in UNITY Biotechnology has recently decreased by 34.44%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for UNITY Biotechnology this week, compared to 0 articles on an average week.
  • Search Interest

    Only 5 people have searched for UBX on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added UNITY Biotechnology to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, UNITY Biotechnology insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.80% of the stock of UNITY Biotechnology is held by insiders.

  • Percentage Held by Institutions

    Only 29.49% of the stock of UNITY Biotechnology is held by institutions.

  • Read more about UNITY Biotechnology's insider trading history.
Receive UBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for UNITY Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

UBX Stock News Headlines

Banks aren’t ready for this altcoin—are you?
The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket change.
UBX Unity Biotechnology, Inc. - Seeking Alpha
See More Headlines

UBX Stock Analysis - Frequently Asked Questions

UNITY Biotechnology's stock was trading at $0.9764 on January 1st, 2025. Since then, UBX stock has decreased by 81.7% and is now trading at $0.1790.

UNITY Biotechnology, Inc. (NASDAQ:UBX) issued its quarterly earnings data on Tuesday, April, 22nd. The company reported ($0.43) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.43).

Shares of UNITY Biotechnology reverse split on Thursday, October 20th 2022.The 1-10 reverse split was announced on Thursday, October 20th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

UNITY Biotechnology (UBX) raised $85 million in an initial public offering (IPO) on Thursday, May 3rd 2018. The company issued 5,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup acted as the underwriters for the IPO and Mizuho Securities was co-manager.

Shares of UBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that UNITY Biotechnology investors own include Plug Power (PLUG), NVIDIA (NVDA), NIO (NIO), Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), Enovix (ENVX) and Nokia (NOK).

Company Calendar

Last Earnings
4/22/2025
Today
7/11/2025
Next Earnings (Estimated)
7/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:UBX
CIK
1463361
Fax
N/A
Employees
60
Year Founded
N/A

Price Target and Rating

High Price Target
$8.00
Low Price Target
$1.00
Potential Upside/Downside
+1,995.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.62)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$25.99 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-246.82%
Return on Assets
-58.81%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.95
Quick Ratio
1.95

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.39 per share
Price / Book
0.46

Miscellaneous

Outstanding Shares
17,212,000
Free Float
16,214,000
Market Cap
$3.08 million
Optionable
Optionable
Beta
0.92
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:UBX) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners